At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed diffuse large B-cell lymphoma of specified subtypes (centroblastic, immunoblastic, T-cell/histiocyte-rich, lymphomatoid granulomatosis type, anaplastic large B-cell, plasmablastic, mediastinal, or intravascular)
- ✓Previously untreated disease
- ✓High-intermediate or high-risk disease defined by age-adjusted international prognostic index score of 2 or 3
- ✓CD20+ disease on initial diagnostic specimen
- ✕Known brain or leptomeningeal metastases
- ✕Primary effusion lymphomas
- ✕Stage I or limited stage II disease confined to an involved-field radiotherapy port
- ✕Acute myocardial infarction within past 3 months
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of R-CHOP and Ibritumomab Tiuxetan (Zevalin) for Elderly Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating darbepoetin alfa, filgrastim, and 7 other interventions for Lymphoma. Completed, enrolled 65 participants across 2 sites.
Detailed Summary
RATIONALE: Monoclonal antibodies such as rituximab and yttrium Y 90 ibritumomab tiuxetan can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining rituximab and combination chemotherapy with yttrium Y 90 ibritumomab tiuxetan may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining rituximab and combination chemotherapy with yttrium Y 90 ibritumomab tiuxetan in treating older patients who have B-cell lymphoma that has not been previously treated.